news

AI-driven biosimilar manufacturing partnership announced

6
SHARES

Artificial intelligence technology will drive manufacture of high-quality biosimilars at scale under a partnership between Sandoz and Just – Evotec Biologics.

AI-driven biosimilar manufacturing partnership announced

Sandoz and Just – Evotec Biologics have announced a partnership to develop and manufacture multiple biosimilars. Within the agreement, Sandoz will gain access to an artificial intelligence (AI)-driven technology platform that delivers fully integrated drug substance development and continuous manufacturing. This will support the expansion of Sandoz’s pipeline to 24 biosimilar assets.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Using AI to manufacture biosimilars

As part of the strategic partnership, both parties share a commitment “to use disruptive technology with lower operational costs to deliver high-quality biosimilars at scale to patients around the world,” according to Sandoz’s CEO Richard Saynor.

“By intensifying and shrinking the footprint of our manufacturing facility using these technologies, we can lower the cost of production,” Randal Bass, EVP Process Design & Biotherapeutic Operations for Just – Evotec Biologics explained in a video published on the company’s Twitter page.

Continuous manufacturing of biologics

Under of the partnership, Sandoz has the option to use Evotec Biologics’ advanced continuous manufacturing process. This state-of-the-art drug development and manufacturing technology delivers enhanced quality and productivity in biologics production.

The agreement “provides us with additional capabilities to support the strategic expansion of our pipeline with new assets and to begin immediately transitioning our early biosimilar pipeline – ensuring continuity in development and manufacturing while Sandoz finalises its planned separation from Novartis. Development of the biosimilars will ramp-up over the coming 12-18 months,” Sandoz’s CEO stated.

Sandoz to boost biosimilar development with manufacturing expansion

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via